Safety and Tolerability of COVID-19 Vaccine in Children With Epilepsy: A Prospective, Multicenter Study.
Pediatr Neurol
; 140: 3-8, 2023 03.
Article
de En
| MEDLINE
| ID: mdl-36577181
ABSTRACT
BACKGROUND:
We designed this study to investigate the effects of the coronavirus disease 2019 (COVID-19) vaccine on epileptic seizures, as well as its adverse effects, in children with epilepsy (<18 years).METHODS:
This anonymous questionnaire study involved a multicenter prospective survey of outpatients and inpatients with epilepsy (ï¼18 years) registered in epilepsy clinics in eight hospitals in six cities of Shandong Province.RESULTS:
A total of 224 children with epilepsy were included in the study. Fifty of them experienced general adverse events after vaccination. The most common local adverse events were pain or tenderness at the injection site. The most common systemic adverse effects were muscle soreness and headache. No severe adverse events were reported. There were no significant differences in the number of antiseizure medications (P = 0.459), gender (P = 0.336), etiology (P = 0.449), age (P = 0.499), duration of disease (P = 0.546), or seizure type (P = 0.475) between the patients with and without general adverse events. We found that the risk of seizure after vaccination was decreased in children who were seizure free for more than six months before vaccination. There was no significant difference in the number of seizures during the first month before vaccination, the first month after the first dose, and the first month after the second dose (P = 0.091).CONCLUSION:
The benefits of vaccination against COVID-19 outweighed the risks of seizures/relapses and severe adverse events after vaccination for children with epilepsy.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Épilepsie
/
COVID-19
Type d'étude:
Clinical_trials
/
Risk_factors_studies
Limites:
Child
/
Humans
Langue:
En
Journal:
Pediatr Neurol
Sujet du journal:
NEUROLOGIA
/
PEDIATRIA
Année:
2023
Type de document:
Article
Pays d'affiliation:
Chine